Laurent Francois Andre Hennequin

This inventor holds 38 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Quinazoline Derivatives. Top assignees: Astrazeneca Ab, Zeneca Limited, Astra Zeneca U.k. Limited. Active years: 2001-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laurent Francois Andre Hennequin. Retrieved from https://idiyas.com/inventor/laurent-francois-andre-hennequin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 38 (Patent Applications = 9)

% Patents Active = 42.1

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.3

ph-index = 13

Forward Citations = 669(Granted Patents)

Location History:

Champigny sur Vesles, FR (2001 - 2002)
Chemin de Vrilly, FR (2003)
Alderley Park, GB (2005 - 2008)
Macclesfield, GB (2007 - 2012)
Cheshire, GB (2013)
Reims Cedex, FR (2001 - 2014)
Cedex, FR (2004 - 2014)
Reims Cedex 2, FR (2015)
Reims, FR (2006 - 2019)

Company Filing History:

Astra Zeneca U.k. Limited

6. 6 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2019

Loading Chart...

Areas of Expertise:

Quinazoline Derivatives

VEGF Inhibitors

Tyrosine Kinase Inhibitors

Antiproliferative Agents

Angiogenesis Inhibitors

Pharmaceutical Compositions

Hyperproliferative Disorders

3-Cyanoquinoline

Cinnoline Compounds

Oxindole Derivatives

Chemical Compounds

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10457664 - Quinazoline derivatives as VEGF inhibitors (2019-10-29),

2. 9040548 - Quinazoline derivatives as VEGF inhibitors (2015-05-26),

3. 8735410 - Quinazoline derivatives as tyrosine kinase inhibitors (2014-05-27),

4. 8642608 - Quinazoline derivatives as VEGF inhibitors (2014-02-04),

5. 8399667 - 4-anilino quinazoline derivatives as antiproliferative agents (2013-03-19),

6. 8293902 - Quinazoline compounds (2012-10-23),

7. 7989460 - Quinazoline derivatives as angiogenesis inhibitors (2011-08-02),

8. RE42353 - Quinazoline derivatives and pharmaceutical compositions containing them (2011-05-09),

9. 7838530 - Quinazoline derivatives as antiproliferative agents (2010-11-23),

10. 7659279 - Quinazoline derivatives and their use in the treatment of cancer (2010-02-09),

11. 7632840 - Quinazoline compounds for the treatment of hyperproliferative disorders (2009-12-15),

12. 7625908 - Quinazoline derivatives (2009-12-01),

13. 7569577 - Quinazoline derivatives as tyrosine kinase inhibitors (2009-08-04),

14. 7504408 - Quinzoline derivatives for use in the treatment of cancer (2009-03-17),

15. 7501516 - Quinoline derivatives and their use as tyrosine kinase inhibitors (2009-03-10),

Title: Innovations of Laurent Francois Andre Hennequin

Introduction

Laurent Francois Andre Hennequin is a distinguished inventor located in Reims, France. With an impressive portfolio of 38 patents, Hennequin has made significant contributions to the field of pharmaceuticals, particularly in the area of VEGF inhibitors.

Latest Patents

Hennequin's latest patents focus on quinazoline derivatives as VEGF inhibitors. These innovations involve quinazoline derivatives of a specific formula, where certain variables represent a range of chemical structures, including halogeno or alkyl groups. These compounds are designed to inhibit the effects of Vascular Endothelial Growth Factor (VEGF), which is pivotal in the treatment of various ailments such as cancer and rheumatoid arthritis. The patents detail processes for their preparation and pharmaceutical compositions that utilize these compounds as active ingredients.

Career Highlights

Hennequin has an accomplished career, marked by his association with prominent companies like AstraZeneca. His work there has significantly influenced the development of new therapeutic strategies, particularly in oncology and inflammatory diseases.

Collaborations

Throughout his career, Hennequin has worked alongside talented individuals, including Andrew Peter Thomas and Elaine Sophie Elizabeth Stokes. These collaborations have fostered a rich environment for innovation and have contributed to the successful development of his patented technologies.

Conclusion

In summary, Laurent Francois Andre Hennequin stands out as a prolific inventor whose work has greatly advanced the pharmaceutical landscape. With 38 patents to his name, his contributions hold promise for future treatments that target critical health challenges.

Profile summary based on public USPTO records.